Pharmaceutical - Respiratory and Pulmonary, Markets & Marketing

Filter

Popular Filters

1 to 25 of 33 results

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

EU5 payers looking to superior clinical efficacy for COPD

EU5 payers looking to superior clinical efficacy for COPD

30-06-2014

Surveyed pulmonologists in the European Union (EU5; France, Germany, Italy, Spain and the UK) estimate…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

06-05-2014

USA-based allergy immunotherapy products and services specialist Greer Laboratories today announced the…

Ares Life SciencesGREER LaboratoriesMarkets & MarketingOralairPharmaceuticalRespiratory and PulmonaryStallergenesUSA

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers

06-04-2014

Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

Report: Global cystic fibrosis market value to treble by 2019

12-03-2014

The global cystic fibrosis market value in seven major countries will jump from $1.2 billion in 2013…

CanadaEuropeKalydecoMarkets & MarketingPharmaceuticalResearchRespiratory and PulmonaryUSAVertex

Skyepharma launches Flutiform in France for asthma

10-02-2014

UK drug delivery specialist Skyepharma has received regulatory approval and agreement on pricing reimbursement…

FlutiformFranceMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

GlaxoSmithKline’s Relvar Ellipta for asthma and COPD launches in the UK

08-01-2014

UK pharma giant GlaxoSmithKline and US partner Theravance today announced the launch of Relvar Ellipta…

GlaxoSmithKlineMarkets & MarketingNorthern EuropePharmaceuticalRelvar ElliptaRespiratory and PulmonaryTheravanceUK

Actelion says PAH drug Opsumit now available in USA

Actelion says PAH drug Opsumit now available in USA

05-11-2013

Actelion has confirmed that Opsumit 10mg, an oral, dual endothelin receptor antagonist for pulmonary…

ActelionMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonary

Theravance and GSK launch Breo Ellipta in USA

Theravance and GSK launch Breo Ellipta in USA

30-10-2013

GlaxoSmithKline and US partner Theravance today announced that Breo Ellipta for COPD is available to…

Breo ElliptaFinancialGlaxoSmithKlineMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and PulmonaryTheravance

Global asthma treatment market to reach $21.6 billion by 2019

09-10-2013

The global asthma treatment market is estimated to reach a value of $21.6 billion by 2019, due not only…

GlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022

29-08-2013

The drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of…

AdvairAnoroBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and PulmonarySpirivaTheravance

Akrikhin expands deal with Merck & Co

08-08-2013

Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

US pulmonologists views on PAH prescribing options

19-07-2013

US pulmonologists surveyed by health care advisory firm Decision Resources consider a drug's effect on…

ActelionBayerMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonaryriociguat

Global asthma market to reach 159 million lifetime cases by 2022

16-06-2013

Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion.…

GlaxoSmithKlineGlobalMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySeretideSingulair

US Appeals Court puts temporary stop on sales of generics of AstraZeneca's Pulmicort Respules

27-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last Friday (May 24) that the US Court of Appeals…

ActavisAstraZenecaGenericsLegalMarkets & MarketingNorth AmericaPharmaceuticalPulmicort RespulesRespiratory and Pulmonary

Asthma preventive drugs market led by GlaxoSmithKline's Advair

26-11-2012

The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

AdvairAstraZenecaGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicort

Stallergenes adds France to roll-out of grass pollen therapy Oralair

22-11-2012

France-based Stallergenes (GENP: FP) has announced the launch in France of Oralair, its grass pollen…

EuropeMarkets & MarketingOralairPharmaceuticalRespiratory and PulmonaryStallergenes

New LABA/LAMA drugs set to fracture COPD market

10-10-2012

The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured…

AdvairBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPfizerPharmaceuticalRespiratory and PulmonarySpiriva

SkyePharma/Mundipharma's Flutiform launched in Germany

23-09-2012

UK-based drug delivery specialist SkyePharma (LSE: SKP) last Friday announced the launch of Flutiform,…

EuropeFlutiformMarkets & MarketingMundipharmaPharmaceuticalRespiratory and PulmonarySkyepharma

Denmark sees first launches of Almirall's Eklira Genuair and ViroPharma's Plenadren

21-09-2012

Spain's largest drugmaker, Almirall (ALM: MC), says that the Danish Health and Medicines Authority has…

AlmirallEklira GenuairEuropeMarkets & MarketingPharmaceuticalPlenadrenRare diseasesRespiratory and PulmonaryViroPharma

Almirall sets up first direct North America presence

05-09-2012

Almirall (ALM: MC), Spain's largest pharmaceutical company, says it has set up a new affiliate in Canada…

aclidiniumAlmirallMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and Pulmonary

Lupin in deal to market Novartis' Onbrez in India, local newspaper reports

30-07-2012

Indian drugmaker Lupin Pharmaceuticals (LOPN: BO) and Swiss major Novartis (NOVN: VX) have entered into…

Asia-PacificLicensingLupinMarkets & MarketingNovartisOnbrezPharmaceuticalRespiratory and Pulmonary

1 to 25 of 33 results

Back to top